← Back to Search

Platelet Rich Plasma Therapy

ACP treatment for Plantar Fasciitis

N/A
Waitlist Available
Research Sponsored by University of Western Ontario, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks, 3,6,12 months
Awards & highlights

Study Summary

Plantar fasciitis presents clinically as pain in the inner heal, which is the result of degeneration of the plantar fascia, an arch supporting ligament of the foot. It manifests predominantly in those subjected to sustained weight bearing or repetitive pounding activities. Plantar fasciitis is the most common cause of inferior foot pain. Although most cases resolving within 6 months, traditional treatment regiments such as orthotics and physiotherapy are occasionally unsuccessful in treating this limitation leading to chronic symptoms (Neufeld & Cerrato, 2008; Rompe, 2009; Roxas, 2005). Platelets are central players in clotting, inflammation and the wound healing response. Research has shown the potential of platelet rich plasma to accelerate wound healing in a variety of conditions including maxillo-fascial and plastic surgery, chronic wound healing and orthopaedics. Autologous Conditioned Plasma (ACP) is a novel treatment that may accelerate the healing of injured tissue. Treatment with ACP involves taking a blood sample from the patient, isolating the platelets and injecting them back into that patient at the injury site

Eligible Conditions
  • Plantar Fasciitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks, 3,6,12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks, 3,6,12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
American Orthopaedic Foot and Ankle Midfoot Scale (AOFAS)
Secondary outcome measures
Plantar Fasciitis Pain/Disability Scale (PFPD
SF-12

Trial Design

2Treatment groups
Active Control
Group I: ACP treatmentActive Control1 Intervention
Group II: Corticosteroid treatmentActive Control1 Intervention

Find a Location

Who is running the clinical trial?

University of Western Ontario, CanadaLead Sponsor
164 Previous Clinical Trials
319,106 Total Patients Enrolled
Arthrex, Inc.Industry Sponsor
44 Previous Clinical Trials
29,742 Total Patients Enrolled
Dianne Bryant, PhDStudy DirectorThe University of Western Ontario
3 Previous Clinical Trials
142 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~10 spots leftby Apr 2025